ASCO 2021: 摘要概览与展望 7| PD-1抑制剂Keytruda冲击胃癌一线疗法新进展!

2021-05-26 K.K MedSci原创

Keytruda与罗氏的赫赛汀、化疗相结合,可使74.4%的HER2阳性转移期胃或胃食管交界癌患者的肿瘤缩小

Keytruda是免疫治疗时代一颗最为璀璨的明珠,药物给癌症治疗带来了突破性进展,同时凭借肺癌适应症一线疗法的顺利拓展,Keytruda已经建立起强大的市场优势,默沙东2018年财报显示,Keytruda销售额已达到71.71亿美元,大涨88%,默沙东公司的Keytruda在许多肿瘤类型中都取得了成功,但在胃癌方面仍然没有成功的例子。胃癌是同样是Keytruda关注的一个重要适应症,目前,Keytruda获批用于胃癌/胃-食管交界处癌三线治疗,Keytruda希望凭借KEYNOTE-061,062,811等逐步扩大胃癌适应症覆盖人群,升级为一线疗法。

默沙东公司在线上美国临床肿瘤学会会议上说,将Keytruda与罗氏的赫赛汀、化疗相结合,可使74.4%的HER2阳性转移期胃或胃食管交界癌患者的肿瘤缩小,这超过了赫赛汀-化疗方案的51.9%。

美国FDA在正式数据公布之前,就已经根据计划中的692名受试者的首批264名患者的中期数据,迅速批准了Keytruda。

默沙东公司临床研究副总裁Scot Ebbinghaus博士在接受采访时说,这项试验正在研究Keytruda阻止肿瘤进展和延长患者生存的效果。

Ebbinghaus说,3期Keynote-811数据显示了 "非常显著的治疗效果"。KEYNOTE-811研究是一项正在进行的全球多中心、随机对照的III期临床研究,纳入患者为既往未经治疗的不可切除或转移性HER2+胃癌/胃食管结合部腺癌;预期寿命>6个月,RECIST v1.1(实体瘤的疗效评价标准)中可测量病灶、器官功能和体力状态良好。在12个月的中位随访中,Keytruda鸡尾酒的中位反应时间为10.6个月,而赫赛汀-化疗组为9.5个月。Keytruda还根除了11.3%的患者的癌症迹象,而对照组只根除了3.1%的患者。

原文出处:

https://www.fiercepharma.com/pharma/merck-details-keytruda-s-herceptin-combo-stomach-cancer-win-as-a-single-agent-nod-s-danger

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1939170, encodeId=25cb19391e0c6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Feb 17 08:50:18 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972950, encodeId=557b9e2950dc, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210622/fd45c38a5bc9471db75440f7f3a8ee93/778cbee9a2754805a0a757918ad76980.jpg, createdBy=44665483639, createdName=张婷, createdTime=Fri Jun 11 22:32:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852668, encodeId=7fa618526685c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Oct 13 16:50:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278947, encodeId=461512e894738, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 28 01:50:18 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968723, encodeId=0ba5968e23f1, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Wed May 26 20:06:56 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968703, encodeId=d299968e0337, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5f5486222, createdName=ms4000001548094280, createdTime=Wed May 26 19:06:01 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968649, encodeId=708496864951, content=her2阳性的PD-1疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed May 26 15:09:43 CST 2021, time=2021-05-26, status=1, ipAttribution=)]
    2022-02-17 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1939170, encodeId=25cb19391e0c6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Feb 17 08:50:18 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972950, encodeId=557b9e2950dc, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210622/fd45c38a5bc9471db75440f7f3a8ee93/778cbee9a2754805a0a757918ad76980.jpg, createdBy=44665483639, createdName=张婷, createdTime=Fri Jun 11 22:32:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852668, encodeId=7fa618526685c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Oct 13 16:50:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278947, encodeId=461512e894738, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 28 01:50:18 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968723, encodeId=0ba5968e23f1, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Wed May 26 20:06:56 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968703, encodeId=d299968e0337, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5f5486222, createdName=ms4000001548094280, createdTime=Wed May 26 19:06:01 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968649, encodeId=708496864951, content=her2阳性的PD-1疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed May 26 15:09:43 CST 2021, time=2021-05-26, status=1, ipAttribution=)]
    2021-06-11 张婷

    赚积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1939170, encodeId=25cb19391e0c6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Feb 17 08:50:18 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972950, encodeId=557b9e2950dc, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210622/fd45c38a5bc9471db75440f7f3a8ee93/778cbee9a2754805a0a757918ad76980.jpg, createdBy=44665483639, createdName=张婷, createdTime=Fri Jun 11 22:32:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852668, encodeId=7fa618526685c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Oct 13 16:50:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278947, encodeId=461512e894738, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 28 01:50:18 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968723, encodeId=0ba5968e23f1, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Wed May 26 20:06:56 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968703, encodeId=d299968e0337, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5f5486222, createdName=ms4000001548094280, createdTime=Wed May 26 19:06:01 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968649, encodeId=708496864951, content=her2阳性的PD-1疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed May 26 15:09:43 CST 2021, time=2021-05-26, status=1, ipAttribution=)]
    2021-10-13 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1939170, encodeId=25cb19391e0c6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Feb 17 08:50:18 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972950, encodeId=557b9e2950dc, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210622/fd45c38a5bc9471db75440f7f3a8ee93/778cbee9a2754805a0a757918ad76980.jpg, createdBy=44665483639, createdName=张婷, createdTime=Fri Jun 11 22:32:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852668, encodeId=7fa618526685c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Oct 13 16:50:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278947, encodeId=461512e894738, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 28 01:50:18 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968723, encodeId=0ba5968e23f1, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Wed May 26 20:06:56 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968703, encodeId=d299968e0337, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5f5486222, createdName=ms4000001548094280, createdTime=Wed May 26 19:06:01 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968649, encodeId=708496864951, content=her2阳性的PD-1疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed May 26 15:09:43 CST 2021, time=2021-05-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1939170, encodeId=25cb19391e0c6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Feb 17 08:50:18 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972950, encodeId=557b9e2950dc, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210622/fd45c38a5bc9471db75440f7f3a8ee93/778cbee9a2754805a0a757918ad76980.jpg, createdBy=44665483639, createdName=张婷, createdTime=Fri Jun 11 22:32:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852668, encodeId=7fa618526685c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Oct 13 16:50:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278947, encodeId=461512e894738, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 28 01:50:18 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968723, encodeId=0ba5968e23f1, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Wed May 26 20:06:56 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968703, encodeId=d299968e0337, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5f5486222, createdName=ms4000001548094280, createdTime=Wed May 26 19:06:01 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968649, encodeId=708496864951, content=her2阳性的PD-1疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed May 26 15:09:43 CST 2021, time=2021-05-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1939170, encodeId=25cb19391e0c6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Feb 17 08:50:18 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972950, encodeId=557b9e2950dc, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210622/fd45c38a5bc9471db75440f7f3a8ee93/778cbee9a2754805a0a757918ad76980.jpg, createdBy=44665483639, createdName=张婷, createdTime=Fri Jun 11 22:32:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852668, encodeId=7fa618526685c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Oct 13 16:50:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278947, encodeId=461512e894738, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 28 01:50:18 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968723, encodeId=0ba5968e23f1, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Wed May 26 20:06:56 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968703, encodeId=d299968e0337, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5f5486222, createdName=ms4000001548094280, createdTime=Wed May 26 19:06:01 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968649, encodeId=708496864951, content=her2阳性的PD-1疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed May 26 15:09:43 CST 2021, time=2021-05-26, status=1, ipAttribution=)]
    2021-05-26 ms4000001548094280

    可以

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1939170, encodeId=25cb19391e0c6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Feb 17 08:50:18 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972950, encodeId=557b9e2950dc, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210622/fd45c38a5bc9471db75440f7f3a8ee93/778cbee9a2754805a0a757918ad76980.jpg, createdBy=44665483639, createdName=张婷, createdTime=Fri Jun 11 22:32:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852668, encodeId=7fa618526685c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Oct 13 16:50:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278947, encodeId=461512e894738, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 28 01:50:18 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968723, encodeId=0ba5968e23f1, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Wed May 26 20:06:56 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968703, encodeId=d299968e0337, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff5f5486222, createdName=ms4000001548094280, createdTime=Wed May 26 19:06:01 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968649, encodeId=708496864951, content=her2阳性的PD-1疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Wed May 26 15:09:43 CST 2021, time=2021-05-26, status=1, ipAttribution=)]
    2021-05-26 JZ Yang

    her2阳性的PD-1疗效

    0

相关资讯

GUT: 质子泵抑制剂的使用可能会增加胃癌的发生率

胃癌是全世界第六大最常见的癌症,癌症相关死亡率则排第三位,慢性幽门螺杆菌感染是胃癌的最强危险因素。根除幽门螺杆菌可减少胃癌的发生。

GUT:中高危胃肠化生患者要定期内镜检查评估肠化生情况,预防胃癌

胃癌(GC)是世界上第五大常见癌症和第三大癌症相关死亡原因,死亡率高的主要原因是发病较晚。超过70%的国家报告了胃癌的高死亡率/发病率(>0.8)。只有日本和韩国的死亡率/发病率较低(分别为0.

胃癌有无转移?影像检查+人工智能可准确预测,避免“白挨一刀”

5月14——15日,2021年中国研究型医院学会数字智能化外科专业委员会学术年会暨第二届国际数字智能化诊疗技术大会在广州召开。中国科学院院士刘允怡、陈孝平及来自国内外的80余位

Gut:可预测胃癌从紫杉醇治疗中获益的基因特征

一个可预测胃癌患者从紫杉醇治疗中获益的首个生物标志物

Gut:胃肠化生的严重程度预测胃癌的发生:一项前瞻性队列研究(GCEP)

胃肠化生(IM)是促进早期胃癌发生的危险因素,建议采用风险分层方法,并建议高危患者(OLGIM III-IV)在2年内接受内镜监测,中危患者(OLGIM II)在5年内接受内镜监测。

Gut:机器学习模式鉴别胃癌紫杉醇生存获益的基因集:来自III期随机临床试验SAMIT的数据分析

胃癌是常见的恶性肿瘤。术前或术后的化疗都能给患者带来生存获益。目前常用的药物有5-FU,铂类以及紫杉醇类药物。有研究报道了预测5-FU以及铂类药物生存获益的标志物。但是对于紫杉醇获益的生物指标仍没有报